ESMO Open

Papers
(The H4-Index of ESMO Open is 47. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Editorial Board242
A phase II study to explore biomarkers for the use of mFOLFOX6/XELOX plus bevacizumab as a first-line chemotherapy in patients with metastatic colorectal cancer (WJOG7612GTR)213
Editorial Board139
87P Characteristics and outcomes of 11 patients with myoepithelial tumors: The Gustave Roussy experience138
94P Efficacy of first-line pembrolizumab in elderly patients with advanced non-small cell lung cancer with high PD-L1 expression132
Letter comments on: Drug–drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of patients with metastatic breast cancer126
PP289 Potential anti-tumour therapy in nasopharyngeal carcinoma: MDM2 siRNA-based approaches121
OP01-2 Changes in the tumor microenvironment in recurrent head and neck squamous cell carcinoma and its implication on efficacy of immune checkpoint inhibitors120
107P Clinicopathologic features of breast cancer patients in a single tertiary hospital in the Philippines100
258P Real-world (rw) outcomes in patients (pts) with hormone receptor-positive and human epidermal growth factor receptor-2-negative (HR+/HER2-) metastatic breast cancer (mBC) treated with chemotherap100
284P Risk assessment for systemic recurrence in HER2-low breast cancer: Evaluating hormone receptors and immunohistochemical profiles99
266O Safety of assisted reproductive techniques in young BRCA carriers with a pregnancy after breast cancer: Results from an international cohort study97
ESMO95
70P Development and validation of a machine learning (ML) nomogram to predict RSClin results and guide adjuvant treatment of node-negative (N0) hormone receptor-positive (HR+)/human epidermal growth f89
70P Invasive lobular breast cancer (ILC), an overlooked subtype in clinical trials87
103P Impact of Prosigna test on treatment decision in lymph node-negative early breast cancer: A prospective multicenter study (EMIT1)87
PP018 PAK1 inhibitor IPA-3 mitigates metastatic prostate cancer-induced bone remodeling85
200P OlympiAD: Exploratory analysis of olaparib vs capecitabine in patients with germline BRCA-mutated (gBRCAm) metastatic breast cancer (mBC)83
118P Real-world treatment patterns and clinical outcomes among high risk, early stage HER2-negative breast cancer (BC) patients in Alberta, Canada82
OP27 A phase II study of neoadjuvant erlotinib for operable stage II or IIIA non-small cell lung cancer with epidermal growth factor receptor activating mutations79
267P Ultrasound-guided injection with or without rehabilitation exercise in breast cancer survivors with subacromial-deltoid bursitis: Long-term results of a pilot randomized clinical study79
47P Sarcoma in the Czech Republic: Update data through 2021 including epidemiology, patients flow and treatment outcomes75
Editorial Board75
51O The European Prospective Investigation into Cancer and nutrition cohort (EPIC): A gateway to rare cancer epidemiological research – Insights from the EPIC Rare Cancers Working Group74
62P Updated overall survival and safety with ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib and harboring KIT exon 11 + 17/18 mutatio67
107P The actin cytoskeleton as a new target structure for metastasizing osteosarcoma66
100P Combinatorial treatment strategies for overcoming the immunotherapy resistance in soft tissue sarcomas66
PP049 Redistribution of 8-oxo-G/AP sites hot spots mediated transcription alteration is a novel and ubiquitous mechanism in EGFR-TKI resistance of NSCLC66
Editorial Board65
8P Clinicopathological features and the role of adjuvant therapy in the management of gastrointestinal verrucous carcinoma65
10P The risk of second primary lymphoma in colorectal cancer: An updated SEER analysis 2000–202063
97P Cost-effectiveness of TTFields in addition to standard systemic therapy for stage IV non-small cell lung cancer patients following progression on or after platinum-based chemotherapy63
129P FDG PET imaging of symptomatic chest wall myositis following stereotactic body radiation therapy (SBRT) for patients with early stage cell lung cancer62
128P Innovative limb salvage: Liquid nitrogen approach in reconstruction after bone tumor resection60
55P The SOS inhibitor BAY293 contributes to amplified vertical inhibition of the MAP kinase pathway in human melanoma cells59
146P The prognosis value of heat-shock proteins in esophagogastric cancer: A systematic review and meta-analysis58
148P Identification of potential predictive biomarkers for ovarian cancer chemotherapy response55
57P Two cases of adult rhabdomyosarcoma of the head and neck successfully treated with pazopanib53
83P Cost-effectiveness analysis of talazoparib maintenance treatment for patients with germline BRCA1/2 mutated HER2-negative advanced breast cancer in China and the US53
174P Endocrine disruptors and life STILe in patients carrying BRCA pathogenic VAriants with breast and/or ovarian CAncer and women without neoplasm: The STILVARCA study52
180P Improving the referral pathway for breast cancer patients: Lessons learnt from 1-year pilot51
63P Redefining the role of CA 19-9 as a prognostic marker in epithelial ovarian cancer51
68P Prognosis of ovarian cancer patients with the Mexican founder mutation (a BRCA1 long genomic rearrangement) compared with other BRCA1/2 mutations49
232P Real-world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom48
22P Emerging role of histone acetyltransferase CBP in breast cancer cells undergoing DNA damage48
39P A validation study of a self-testing capillary kit, the rhelise kit for therapeutic dose monitoring (TDM) of tamoxifen, Z-endoxifen, and 4-hydroxytamoxifen in breast cancer patients48
63P Activity and safety of FGFR inhibitors in pan-cancer patients with FGF/FGFR alterations and advanced malignancies: A pooled analysis of 7 phase I/II trials48
74P Obesity regulates tumor progression and sensitivity to checkpoint blockade through the diet-microbiota-immunity axis47
37P Dose transition pathways for time-to-event continual reassessment method (TITE-CRM): Will imposing a waiting time result in better performance?47
0.084417104721069